---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-282054"
form_type: "8-K"
ticker: "VCNX"
cik: "0001205922"
company_name: "VACCINEX, INC."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:20:27.562308+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vaccinex reports 100% recurrence-free at 24 months in Stage III melanoma triple combination

## Summary
- Triple combo (pepinemab+nivolumab+ipilimumab) achieved 100% recurrence-free survival at 24 months vs <40% for dual combos.
- LAG-3 upregulation identified as resistance mechanism to pepinemab+nivolumab; rationale for triple with LAG-3 inhibitor.
- Pepinemab combinations induced tertiary lymphoid structures and CD26hi CD4+ T cells in tumors.
- Phase 1/2 trial enrolling for pepinemab+trastuzumab+DC vaccine in HER2+ metastatic breast cancer (NCT05378464).
- Interim analysis of KEYNOTE-B84 (pepinemab+KEYTRUDA in HNSCC) expected in Q1 2023.

## SEC filing metadata
- accession: 0001193125-22-282054
- form_type: 8-K
- ticker: VCNX
- cik: 0001205922
- company_name: VACCINEX, INC.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1205922/000119312522282054/0001193125-22-282054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1205922/000119312522282054/d408251d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-282054
- JSON: https://secwatch.observer/filing/0001193125-22-282054.json
- Plain text: https://secwatch.observer/filing/0001193125-22-282054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.